Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating
patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast
cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated
irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
Phase:
Phase 2
Details
Lead Sponsor:
Joel Neal Stanford University
Collaborators:
National Cancer Institute (NCI) Nektar Therapeutics